Peptides vs. Anabolic Steroids: What the Efficacy Data Show

Can Peptides Replace Steroids?

People often ask whether a course of ipamorelin and CJC-1295 can add as much muscle as a testosterone cycle. Based on the human data available as of October 2026, it can't, and the gap isn't close. High-dose testosterone has randomized trials showing large increases in lean mass and strength. The peptides lifters use for muscle have no trial showing a strength increase, and very few that measured muscle at all.

The two classes work through different systems and rest on very different amounts of evidence. This page sets out what each has been shown to do in people and flags where common claims go further than the data. For a broader comparison that also covers exogenous growth hormone and insulin, see our overview of peptides vs. traditional anabolics.

Different Engines: Androgen Receptor vs. Growth Hormone

Anabolic-androgenic steroids (AAS) such as testosterone bind the androgen receptor inside muscle cells and many other tissues. That raises muscle protein synthesis and enlarges muscle fibers directly, and the effect scales with dose. In a 2001 trial, 61 healthy young men had their own testosterone suppressed and then received 25 to 600 mg of testosterone enanthate weekly for 20 weeks. Fat-free mass rose by 3.4, 5.2 and 7.9 kg at the 125, 300 and 600 mg doses, and leg press strength tracked testosterone levels.

Most peptides sold for muscle don't touch the androgen receptor. Growth hormone secretagogues such as ipamorelin, and GHRH analogs such as CJC-1295, prompt the pituitary to release more of the body's own growth hormone (GH). GH in turn raises insulin-like growth factor 1 (IGF-1), mostly made in the liver. These peptides act a step or two upstream of muscle, and their effect is capped by how much GH and IGF-1 the body makes in response.

Forum guides often claim that the GH/IGF-1 route adds new muscle fibers (hyperplasia). We found no human study showing hyperplasia from GH or a secretagogue. Some of the "fuller" look users describe may be water, since fluid retention is a consistent effect of raising GH in trials.

A Head-to-Head Look at the Numbers

No trial has compared a peptide with a steroid directly. The table below sets separate placebo-controlled trials side by side. They differ in population and dose, so read it as a rough picture rather than a ranking. MK-677 (ibutamoren) is included because it acts on the same ghrelin receptor as ipamorelin and has a year-long trial that measured body composition, though it's an oral drug, not a peptide.

Two patterns stand out. Testosterone raised strength even without training: in the 1996 trial, men who got testosterone but didn't lift still gained more on the bench press (+9 kg vs. -1 kg) and squat (+16 kg vs. +3 kg) than men on placebo. Raising GH, by contrast, added lean mass without measurable strength, in young adults given GH itself and in older adults given MK-677. Part of that lean mass may be fluid: the GH review found more soft-tissue swelling in treated participants, and mild leg swelling was a common side effect of MK-677.

The fat-loss case is weaker than forum guides suggest. After a year on MK-677, total fat mass and visceral fat didn't differ from placebo, while fasting glucose went up and insulin sensitivity fell. No trial has measured fat loss with ipamorelin or CJC-1295 in healthy adults.

The record for the two most popular injectable secretagogues is thin. CJC-1295's human data come from two 2006 studies in healthy adults: after one injection, GH stayed raised for 6 days or more and IGF-1 for 9-11 days. Neither study measured muscle, and in December 2024 FDA reviewers told the agency's compounding advisers that no published article discussed CJC-1295's effectiveness in humans. Ipamorelin's human data are an IV dosing study in 48 healthy men and a Phase 2 trial in bowel recovery after abdominal surgery, which missed its primary endpoint (median time to first tolerated meal 25.3 vs. 32.6 hours, not significant), according to an October 2024 FDA briefing. That's why we rate both as moderate evidence: limited human data on hormone levels, none on the outcomes lifters care about.

The trial doses also don't match how people use these peptides. The 2006 CJC-1295 trials gave weight-based doses, and 30-60 mcg/kg was the best tolerated. Users on peptide forums mostly describe Mod GRF 1-29 (CJC-1295 without the DAC modification) plus ipamorelin, 100-300 mcg of each by subcutaneous injection at bedtime, often five days on and two off. No trial has tested that combination for muscle or strength. Our article on peptide cycling strategies covers those on/off schedules.

Side Effects: Neither Option Is Free

In the 2001 testosterone trial, hemoglobin rose and HDL cholesterol fell as the dose went up. The longer-term risks lifters discuss most, including suppressed natural testosterone production after a cycle, are covered in our long-term comparison of peptides and anabolics.

The view that secretagogues are low risk mostly reflects how little they've been studied. FDA's 2024 review of CJC-1295 describes injection-site reactions in about 70% of participants after a single dose, plus flushing, headache, diarrhea and a faster heart rate. A Phase 2 trial in HIV-associated lipodystrophy was stopped after a participant had a fatal heart attack; the attending physician blamed undiagnosed coronary artery disease, and the data were never published. In the ipamorelin surgery trial, the ipamorelin group had more low potassium, insomnia and high blood sugar than the placebo group. Users commonly report water retention, flushing, numb or tingling hands, and lethargy.

Efficacy You Don't See on the Platform

BPC-157 and TB-500 come up in this comparison for a different reason. Nobody claims they build muscle. Lifters use them hoping to recover from tendon and ligament injuries so they can keep training, and the evidence for that use is mostly animal data.

For BPC-157, a synthetic pentadecapeptide originally isolated from gastric juice, the rodent work is consistent. In a 2006 rat study, daily BPC-157 injections after the Achilles tendon was cut from the heel bone improved function and tendon strength compared with controls. But a 2025 systematic review in orthopaedic sports medicine found that 35 of the 36 studies it included were preclinical. As of October 2026, the human data are three small, uncontrolled pilots: knee injections for chronic pain, bladder instillations for interstitial cystitis, and an IV safety study in two adults. No controlled human trial has published results, so we rate BPC-157's evidence as emerging.

TB-500 is a short synthetic fragment of thymosin beta-4. As of April 2026, FDA's compounding safety page says the agency hasn't found any human exposure data for the fragment, and trials of the full protein don't carry over, so we rate TB-500 as preliminary.

User reports are split. Users commonly describe 250-500 mcg of BPC-157 a day by subcutaneous injection, often near the injury, for several weeks. Some on peptide forums describe clear improvement, while others report no change after a month or more. Injuries that would have healed anyway, expectation effects and inconsistent gray-market products could all explain the gap, and without a controlled trial there's no way to tell them apart.

Lifters often argue that strength on steroids climbs faster than tendons adapt, so healing peptides make a sensible add-on. Nobody has tested whether BPC-157 or TB-500 lowers injury rates in steroid users, or in anyone else.

Status in Sport and Law

As of October 2026, WADA's 2026 Prohibited List bans every compound on this page at all times. Anabolic steroids fall under S1. CJC-1295, ipamorelin and MK-677 are named under S2.2.4 as growth hormone releasing factors. TB-500 is named under S2.3 as a thymosin beta-4 derivative, and BPC-157 is named under S0, non-approved substances. None of the peptides discussed here is approved as a medicine anywhere, while testosterone is a prescription medicine. The ethical questions around peptide use go beyond what's on the banned list.

What We Still Don't Know

• Strength in trained lifters. No trial has tested whether any GH secretagogue increases strength in young, trained people.
• What stays. No study has measured how much lean mass gained on a GH-raising peptide remains after stopping.
• Stacking with testosterone. A 2020 review of secretagogues in men with low testosterone proposed them as add-ons to testosterone therapy, but noted that data on their clinical efficacy "largely remain lacking."
• BPC-157 in human tendons. A University of Arkansas pilot of daily BPC-157 injections after rotator cuff surgery (20 patients, placebo-controlled) is registered to start in January 2027. It would be the first controlled test, though a small one.
• Long-term safety. BPC-157 and TB-500 have no controlled safety data, and the controlled data on ipamorelin and CJC-1295 cover weeks, not the months users describe.